24/7 Market News Snapshot 17 March, 2025 – Cel-Sci Corporation (NYSE:CVM)

March 17, 2025

DENVER, Colo., 17 March, 2025 (247marketnews.com) – (NYSE:CVM) are discussed in this article.
CEL-SCI Corporation (CVM) opened trading at $0.32 but has since experienced a dip, currently valued at $0.288, which marks a decline of approximately 5.26% from the previous close of $0.304. Despite this downward trend, the trading volume reached an impressive 16.06 million shares, indicating robust investor interest despite selling pressures. This significant volume hints at potential volatility and presents opportunities for strategic traders as they monitor key technical indicators to assess future support and resistance levels. Investors are advised to approach the situation with caution amid these fluctuations.

In a recent development, CEL-SCI has received encouraging feedback from the U.S. Food and Drug Administration (FDA) regarding the Statistical Analysis Plan (SAP) for its confirmatory Registration Study of Multikine (Leukocyte Interleukin, Injection). This treatment is being evaluated as a neoadjuvant option for patients diagnosed with locally advanced head and neck cancer who have not yet received treatment. The FDA has communicated that no further response is necessary from CEL-SCI and has expressed no additional comments on the confirmatory study protocol.

Geert Kersten, CEO of CEL-SCI, emphasized the importance of their strong clinical data, particularly in survival rates, reinforcing Multikine’s potential to benefit the approximately 70% of patients with low PD-L1 tumor expression, a demographic often underserved by current therapies. CEL-SCI has invested over $200 million in the development of its specialized manufacturing facility, capable of producing over 12,000 treatments annually, to ensure that Multikine can be brought to market efficiently.

Moreover, the company’s completed Phase 3 study revealed striking five-year survival rates; patients receiving Multikine showed a significant survival rate of 73%, compared to 45% in control subjects. With plans to enroll 212 patients in the upcoming confirmatory Registration Study, CEL-SCI is focused on enhancing treatment outcomes and aims to explore strategic partnerships to secure non-dilutive funding for this vital phase, thereby potentially reshaping the landscape of cancer treatment.

Related news for (CVM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.